Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA223976,10.1016/j.jpedsurg.2023.10.004,J Pediatr Surg,37919169,https://pubmed.ncbi.nlm.nih.gov/37919169,CDK4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric Sarcomas,2023,"Pediatric Sarcomas, 3D Bioprinting, Cdk 4/6 Inhibitors, Lerociclib","Janet R Julson, Sara C Horton, Colin H Quinn, Andee M Beierle, Laura V Bownes, Jerry E Stewart, Jamie Aye, Karina J Yoon, Elizabeth A Beierle","Background: Sarcomas are a heterogenous collection of bone and soft tissue tumors. The heterogeneity of these tumors makes it difficult to standardize treatment. CDK 4/6 inhibitors are a family of targeted agents which limit cell cycle progression and have been shown to be upregulated in sarcomas. In the current preclinical study, we evaluated the effects of lerociclib, a CDK4/6 inhibitor, on pedi(Read more on Pubmed)",Pending Annotation,Pending Annotation,Pending Annotation,Pending Annotation,Restricted Access,37919169,c795c2c8-de28-4c0d-941d-cadc868c73aa,syn52564679
